Development asset linked to United Therapeutics Europe in public FDA and regional records.
pharma Β· Breast Cancer Β· Prostate Cancer Β· UTHR
United Therapeutics Europe
United Therapeutics Europe Ltd
United Therapeutics Europe drug portfolio β 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1000 Spring Street, Silver Spring, Maryland 20910, US HQ
1996 Founded
1,443 Employees
Public company Type
UTHR Β· NYSE Ticker
Company details
- Status
- Public
- HQ
- 1000 Spring Street, Silver Spring, Maryland 20910, US
- Founded
- 1996
- Employees
- 1,443
- Programs
- 1032
- Drugs
- 612
- Patents
- 3720
United Therapeutics Europe pipeline
Portfolio lens on 200 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
United Therapeutics Europe drug portfolio β 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
- Target
- Integrin alpha-IIb/beta-3
- Mechanism
- Integrin alpha-V/beta-3 inhibitor
-
abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in United Therapeutics Europe's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
-
acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 1.
- Target
- Carbonic anhydrase 1
- Mechanism
- Carbonic anhydrase XII inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
afatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
agalsidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in United Therapeutics Europe's portfolio. Molecular target: Globotriosylceramide.
- Target
- Globotriosylceramide
- Mechanism
- Globotriosylceramide hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bilirubin.
- Target
- Bilirubin
- Mechanism
- Bilirubin sequestering agent
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
alemtuzumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CAMPATH-1 antigen.
- Target
- CAMPATH-1 antigen
- Mechanism
- CAMPATH-1 antigen inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Mechanism: Adrenergic receptor alpha-1 agonist.
- Mechanism
- Adrenergic receptor alpha-1 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor alpha-1 agonist
-
aliskiren
Cardiovascular system (C09)Cardiovascular system (C09) compound in United Therapeutics Europe's portfolio. Mechanism: Renin inhibitor.
- Mechanism
- Renin inhibitor
-
aliskiren hemifumarate
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Renin.
- Target
- Renin
- Mechanism
- Renin inhibitor
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (Ξ΄lngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in United Therapeutics Europe's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
allopurinol
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.
- Target
- Xanthine dehydrogenase/oxidase
- Mechanism
- Xanthine dehydrogenase inhibitor
-
alogliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Mechanism: Dipeptidyl peptidase IV inhibitor.
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
alpelisib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.
- Target
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
- Mechanism
- PI3-kinase p110-alpha subunit inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha antagonist
-
US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in United Therapeutics Europe's portfolio.
-
US regulatory status: approved. Molecular target: Amiloride-sensitive sodium channel, ENaC.
- Target
- Amiloride-sensitive sodium channel, ENaC
- Mechanism
- Amiloride-sensitive sodium channel, ENaC blocker
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
amino acids
Blood and blood forming organs (B05)US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in United Therapeutics Europe's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
- Target
- Ferriprotoporphyrin IX
- Mechanism
- Ferriprotoporphyrin IX inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Mechanism: Removal of necrotic tissue.
- Mechanism
- Removal of necrotic tissue
-
anakinra
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.
- Target
- Interleukin-1 receptor type 1
- Mechanism
- Interleukin-1 receptor antagonist
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in United Therapeutics Europe's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
apixaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor agonist
-
arginine
Various (V03)Various (V03) compound in United Therapeutics Europe's portfolio.
-
aripiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
- Target
- Ferriprotoporphyrin IX
- Mechanism
- Ferriprotoporphyrin IX inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
artesunate
Antiparasitic products (P01)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
asparaginase
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Molecular target: Cytochrome b.
- Target
- Cytochrome b
- Mechanism
- Cytochrome b inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in United Therapeutics Europe's portfolio.
-
US regulatory status: approved.
-
axitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: C55-isoprenyl pyrophosphate.
- Target
- C55-isoprenyl pyrophosphate
- Mechanism
- C55-isoprenyl pyrophosphate inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
bazedoxifene
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in United Therapeutics Europe's portfolio. Mechanism: Estrogen receptor modulator.
- Mechanism
- Estrogen receptor modulator
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
beclometasone
Respiratory system (R03)Respiratory system (R03) compound in United Therapeutics Europe's portfolio.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
binimetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
-
botulinum toxin type a
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in United Therapeutics Europe's portfolio. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
caffeine
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Mechanism: Mineral supplement.
- Mechanism
- Mineral supplement
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
capsaicin
Nervous system (N01)US regulatory status: approved. Molecular target: Transient receptor potential cation channel subfamily V member 1.
- Target
- Transient receptor potential cation channel subfamily V member 1
- Mechanism
- Vanilloid receptor opener
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cediranib maleate
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in United Therapeutics Europe's portfolio.
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
cetrorelix
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in United Therapeutics Europe's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
- Target
- Ferriprotoporphyrin IX
- Mechanism
- Ferriprotoporphyrin IX binding agent
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in United Therapeutics Europe's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
cladribine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in United Therapeutics Europe's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Bile acids.
- Target
- Bile acids
- Mechanism
- Bile acids sequestering agent
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenocorticotropic hormone receptor.
- Target
- Adrenocorticotropic hormone receptor
- Mechanism
- Melanocortin receptor 2 agonist
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in United Therapeutics Europe's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
covid-19 vaccine (recombinant, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in United Therapeutics Europe's portfolio. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein vaccine antigen
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 2A.
- Target
- 5-hydroxytryptamine receptor 2A
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Alanine racemase.
- Target
- Alanine racemase
- Mechanism
- Alanine racemase inhibitor
-
US regulatory status: approved. Molecular target: Voltage-gated potassium channel.
- Target
- Voltage-gated potassium channel
- Mechanism
- Voltage-gated potassium channel blocker
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Mechanism: Unknown.
- Mechanism
- Unknown
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
US regulatory status: approved. Molecular target: Muscle-type nicotinic acetylcholine receptor.
- Target
- Muscle-type nicotinic acetylcholine receptor
- Mechanism
- Muscle-type nicotinic acetylcholine receptor partial agonist
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
defatted powder of arachis hypogaea l., semen (peanuts)
Various (V01)Various (V01) compound in United Therapeutics Europe's portfolio. Mechanism: Food allergy desensitisation.
- Mechanism
- Food allergy desensitisation
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in United Therapeutics Europe's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
desloratadine
Respiratory system (R01)US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Mechanism: Vasopressin receptor agonist.
- Mechanism
- Vasopressin receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in United Therapeutics Europe's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved.
-
dinutuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Disialoganglioside GD2.
- Target
- Disialoganglioside GD2
- Mechanism
- Disialoganglioside GD2 binding agent
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in United Therapeutics Europe's portfolio.
-
diphtheria (d), tetanus (t), pertussis (whole cell) (pw) and hepatitis b (rdna) (hbv) vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in United Therapeutics Europe's portfolio.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: 3',5'-cyclic phosphodiesterase.
- Target
- 3',5'-cyclic phosphodiesterase
- Mechanism
- 3',5'-cyclic phosphodiesterase inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor alpha-1 antagonist
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in United Therapeutics Europe's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Progesterone receptor agonist
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records. Molecular target: Fibroblast growth factor receptor 1.
- Target
- Fibroblast growth factor receptor 1
- Mechanism
- Fibroblast growth factor receptor 1 inhibitor
-
ebola vaccine (ad26.zebov-gp [recombinant])
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in United Therapeutics Europe's portfolio. Molecular target: Envelope glycoprotein.
- Target
- Envelope glycoprotein
- Mechanism
- Envelope glycoprotein vaccine antigen
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
emtricitabine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to United Therapeutics Europe in public FDA and regional records.